Acasti Pharma invited to present the CaPre study results at National Lipid Association Scientific Sessions

Acasti Pharma announced that it has received an invitation to present the CaPre (omega-3 phospholipid) study results at the National Lipid Association Scientific Sessions in Philadelphia, May 18-21, 2017. Acasti will present the results of its ‘Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre.

Acasti CEO, Pierre Lemieux said that The selection of CaPre data for a poster presentation at this key medical meeting underscores the importance of providing the medical community with new information about therapy advancements in the treatment of hypertriglyceridemia. Data to be presented will highlight Acasti’s commitment to providing hypertriglyceridemia patients and treating physicians with a well-absorbing omega-3 therapeutic that may also have a positive impact on the major lipids associated with cardiovascular disease risk.

Acasti has successfully completed two Phase 1 and two Phase 2 clinical trials with CaPre for the treatment of hypertriglyceridemia. The outcome of the recent End-of-Phase 2 Meeting with the USFDA confirmed that the Phase 3 program is on track to start late 2017.

CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids that help them to be better absorbed into the body. This allows for enhanced bioavailability and EPA and DHA blood levels compared to the “esterified” fish-oil omega-3 options such as LOVAZA.